Daiwa Securities Group Inc. - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 1 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Daiwa Securities Group Inc. ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2020$2,0000.0%5330.0%0.00%
Q1 2020$2,000
-33.3%
5330.0%0.00%
Q4 2019$3,0000.0%5330.0%0.00%
Q3 2019$3,0000.0%5330.0%0.00%
Q2 2019$3,000
+50.0%
533
+37.4%
0.00%
Q1 2019$2,0000.0%3880.0%0.00%
Q4 2018$2,0000.0%3880.0%0.00%
Q3 2018$2,000
-33.3%
3880.0%0.00%
Q2 2018$3,0000.0%3880.0%0.00%
Q1 2018$3,0003880.00%
Other shareholders
PROGENICS PHARMACEUTICALS IN shareholders Q3 2020
NameSharesValueWeighting ↓
Broadfin Capital, LLC 17,902,338$135,342,0005.88%
TIGER MANAGEMENT L.L.C. 1,288,454$9,741,0001.91%
Phocas Financial Corp. 1,047,181$7,917,0000.69%
TUDOR INVESTMENT CORP ET AL 2,370,503$17,921,0000.62%
EAM Investors, LLC 553,309$4,183,0000.58%
Baker Brothers Advisors 4,449,797$33,640,0000.34%
TFS CAPITAL LLC 463,740$3,506,0000.33%
FEDERATED HERMES, INC. 13,508,290$102,123,0000.32%
Rotella Capital Management, Inc. 36,473$276,0000.24%
OXFORD ASSET MANAGEMENT LLP 1,103,848$8,351,0000.18%
View complete list of PROGENICS PHARMACEUTICALS IN shareholders